Form 4: Pfizer Director Shantanu Narayen Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director Shantanu Narayen reports acquisition of phantom stock units representing deferred director's compensation.
Summary
- On March 31, 2025, Shantanu Narayen, a director of Pfizer Inc., acquired 1,973.165 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $25.34.
- Following the transaction, Narayen directly owns 159,173.257 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of phantom stock units aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Acquisition of phantom stock units. |
| 04/02/2025 | Date of report signature. |
Keywords
Form 4, Pfizer, Director, Shantanu Narayen, Phantom Stock Units, Deferred Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.